Our reports provide an independent, expert view supported by robust and innovative data interrogation and analysis.

Refine Sector
Sub-Category
Clear
Publish Date
Clear
Region
Clear
Clear All
Sort by:
Frontier Pharma: Head and Neck Cancer – Immunotherapies and Signal Transduction Inhibitors Dominate First-in-Class Innovation

Published: Mar-2017

Head and neck squamous cell carcinoma is the sixth most common cancer, and its incidence is rising. The term head and.....

$6995
More Info
Frontier Pharma: Fatty Liver Disease – High Degree of First-in-Class Innovation, Dominated by Nuclear Receptor-Targeting NASH Products

Published: Mar-2017

Fatty liver disease (FLD) comprises a spectrum of chronic liver disorders characterized by excessive lipid accumulation.....

$6995
More Info
Frontier Pharma: Melanoma Therapeutics – Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation

Published: Jan-2017

Melanoma is a type of cancer that begins in the melanocytes, often in moles or other pigmented tissues. It most commonly.....

$6995
More Info
Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential

Published: Jan-2017

Immunology is a large therapy area characterized by disorders of the immune system – specifically an aberrant immune.....

$6995
More Info
Frontier Pharma: Type 2 Diabetes Mellitus – GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

Published: Dec-2016

Type 2 diabetes mellitus (T2DM) is a chronic, progressive and serious metabolic disorder characterized by hyperglycemia.....

$6995
More Info
Frontier Pharma: Hepatitis C – Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Published: Dec-2016

Hepatitis C is a blood-borne viral infection characterized by chronic inflammation of the liver. Although patients may.....

$6995
More Info
Frontier Pharma: Asthma Therapeutics – Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Published: Nov-2016

Asthma is a chronic condition affecting the respiratory system, with disease occurrence linked to both genetic and environmental.....

$6995
More Info
Frontier Pharma: Glioblastoma Multiforme – Cancer Immunotherapies Dominate First-in-Class Product Innovation

Published: Sep-2016

Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is the most common and aggressive human.....

$6995
More Info
Frontier Pharma: Ophthalmology Therapeutics – Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

Published: Sep-2016

The visual system, including the eye and its surrounding structures, can be affected by a number of pathological conditions......

$6995
More Info
Frontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes

Published: Aug-2016

Pain, and in particular chronic pain, is a significant global health issue. While pain is not considered a disease in.....

$6995
More Info
Sort by: